VINCENT JUNIEN

About VINCENT JUNIEN

Jean-Louis Junien is a highly regarded pharmaceutical industry executive and a senior advisor associated with Inventiva, where he previously served in governance roles before taking on a scientific advisory position. At Inventiva, a listed biopharmaceutical company focused on developing oral small molecules for significant unmet medical needs, he helped strengthen the company’s scientific governance and the link between R&D strategy, medical expertise, and long-term value creation. Inventiva states that he was a member of the Board of Directors and later became Chairman of the Scientific Advisory Board, which was created to provide high-level external scientific review of the company’s development programs. His professional background is defined by extensive experience in the pharmaceutical sector, built through senior scientific and leadership responsibilities. Inventiva describes him as a senior executive with broad industry experience, which explains his important role in guiding the company’s scientific priorities. His contribution has been particularly relevant in the therapeutic areas central to Inventiva’s strategy, including fibrosis, lysosomal storage disorders, and oncology. His governance responsibilities also reflected a deep understanding of clinical development, R&D validation, and the need to align science with corporate strategy. At Inventiva, Jean-Louis Junien stands out for his ability to support complex development programs in areas with high unmet medical need, especially MASH/NASH and other inflammatory or metabolic diseases. The creation of the Scientific Advisory Board under his chairmanship was a meaningful strategic milestone, designed to accelerate and de-risk discovery programs, inform R&D decisions, and bring in top-tier external scientific insight. His profile reflects a rare combination of scientific credibility, governance experience, and industrial perspective, with a consistent focus on pipeline quality and the rigor of development choices.